All

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
9 September 2020

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases

LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...

Read more
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9 September 2020

Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
2 September 2020

BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease

As part of the collaboration, BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker...

Read more
Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field
30 July 2020

Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field

Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support...

Read the press release
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
30 July 2020

Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...

Read the press release
Clim8 raises €2.75m Series A funding
27 July 2020

Clim8 raises €2.75m Series A funding

The French company, founded in 2016, is a leader in the connected textiles market with its intelligent and patented thermal technologies. With more than 50% of its sales...

Read the press release
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
21 July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...

Read the press release
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
2 July 2020

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...

Read more
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
2 July 2020

CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...

Read more
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
25 June 2020

Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse